Trusted Resource for Clinical Trials, Protocols & Progress
Special populations such as pediatrics and geriatrics are rarely included in FIH trials. However, advanced therapies (ATMPs), gene therapies, and immuno-oncology products require additional safeguards, such as long-term follow-up and immunogenicity monitoring. Trials involving high-risk biologics often require staggered dosing and hospital-based monitoring facilities.
Click to read the full article.
Oncology trials in Europe face specific challenges:
Recruitment: Competition among multiple oncology trials in major cancer centers
Ethics: Balancing patient risk with access to potentially life-saving therapies
Costs: Oncology trials are resource-heavy, requiring advanced imaging, biomarker testing, and complex monitoring
Rare disease trials often face:
Geographic dispersion of patients across multiple EU states
Regulatory heterogeneity despite harmonization efforts
High trial costs due to individualized therapies
Rare disease, pediatric, and ATMP trials often carry higher risk, requiring increased insurance premiums. Decentralized trials with direct-to-patient IMP delivery may also raise insurer concerns, necessitating careful policy negotiation.
Click to read the full article.
DCT adoption in the EU must account for:
Pediatrics: Additional parental consent and child assent processes in eConsent models.
Rare Diseases: Decentralization helps overcome geographic dispersion of small patient populations.
Oncology: DCTs support frequent monitoring needs but must ensure robust adverse event reporting.
Advanced Therapies (ATMPs): Manufacturing and administration complexities limit decentralization potential.
Brexit’s impact is particularly significant in:
Advanced Therapies (ATMPs): Dual oversight from EMA CAT and MHRA.
Rare Diseases: Cross-border recruitment challenges due to small patient populations.
Decentralized Trials: Diverging acceptance of telemedicine and direct-to-patient models in the EU and UK.
Oncology: Parallel submissions complicate large-scale Phase III cancer trials.
Inspections of decentralized and digitalized trials are evolving. EMA has emphasized validation of remote monitoring tools, GDPR-compliant data access, and transparency in eConsent. Member States focus more on practical execution of remote visits and IMP storage at patient homes. ATMP and rare disease trials receive heightened scrutiny due to their complexity and risk profiles.
Click to read the full article.
Adaptive pathways demand tailored approaches in:
Pediatrics: Flexible designs support extrapolation of adult data to children.
Rare Diseases: Small populations benefit from adaptive recruitment and Bayesian inference.
Digital Trials: Use of eCOAs and decentralized platforms facilitates adaptive data collection.
RWE strategies must adapt to:
Pediatrics: Registries capturing long-term pediatric safety data
Decentralized Trials: Wearables and telemedicine feeding real-world datasets
Cross-Border Data Use: Harmonization challenges across GDPR regimes
Post-COVID-19 Environment: Increased reliance on RWE due to disrupted trial conduct
Certain trials receive expedited timelines:
COVID-19 or public health emergency trials: Accelerated reviews possible
Pediatric trials: Summary results within 6 months
Rare disease trials: Often require flexible RFI handling due to limited data
